Follow on Immune / Transcription Modulators Targeting p-STAT3

WP1220 is an analog of WP1066 being developed for topical, dermatological conditions. Mycosis Fungoides or MF, the most common variant of CTCL, is a disease with symptomatic, disfiguring skin lesions. STAT3, an oncogenic transcription factor, has been identified as a critical regulator of MF, whereby the activation of STAT3 through phosphorylation (p-STAT3) has been linked to tumor proliferation and suppression of immune responses. Preclinical testing demonstrated that WP1220, a synthetic compound, potently inhibits the activity of p-STAT3 and the growth of CTCL cell lines.

Target Indication:

Topical Treatment of CTCL


Our Clinical Studies

Sign Up For Alerts